Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema

Clinical & Experimental Allergy, 04/25/2012

Treatment with recombinant human C1 inhibitor (rhC1–INH) provides fast–onset relief for an hereditary angioedema (HAE) attack, with a high rate of therapeutic response maintained throughout subsequent attacks.

Print Article Summary Cat 2 CME Report